{"name":"Ascendis Pharma A/S","slug":"ascendis-pharma-a-s","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"TransCon hGH","genericName":"TransCon hGH","slug":"transcon-hgh","indication":"Treatment of growth hormone deficiency in children and adults","status":"phase_3"}]}],"pipeline":[{"name":"TransCon hGH","genericName":"TransCon hGH","slug":"transcon-hgh","phase":"phase_3","mechanism":"TransCon hGH is a long-acting human growth hormone (hGH) analog that uses a proprietary technology called TransCon to extend its half-life.","indications":["Treatment of growth hormone deficiency in children and adults"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxOMFZlNzBaVnBMZ0Y4N1Z5d1JXUHhabTExYjdZd2pqTHNxSE12VTJSYnd3TGpnbWY1S1BUOXpSckZna2dGTWZFcDV5SGNMa3VPd1RqVFZ4dldfNjNNQ2l2S3EyMmQ2YWozcVZyM05meEFOOHM4empCSzlZQkhSdzhKUW1BQjBmdl9CelU5MTFKSkgwYV9iZTBZcHdNNGpzRmc2QVVRUlNFeEVIUU5ndmtUM3hkNmdEejZGcW9ZYlJLZTd5a3ZVSHdtZklVMEZFZXd2?oc=5","date":"2026-04-08","type":"pipeline","source":"Quiver Quantitative","summary":"Ascendis Pharma A/S Announces Direct Listing of Ordinary Shares on Nasdaq Effective April 20, 2026 - Quiver Quantitative","headline":"Ascendis Pharma A/S Announces Direct Listing of Ordinary Shares on Nasdaq Effective April 20, 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AJBVV95cUxPNkZUdFRYVmFIRFY0MThiWmxybDRUUXJLUjZ5clZxWC1nNzJwVjJVcFh6anE5TUx1bGNfc282UnlIbHBUZDJOMWtnYS1NZDRWVHE3LXNFTDdMcmU2YmZnX1RzNXNSRUNDTHRQTVpEUnFaazB2dnJvald3WmZoWEdGLUFPMklJUmU2dEQ4ZXUzQ2o3Y0ZWTHlwYkxuTEdibDd6V3F5MWZQQ1NlNFN4NmhIWGhjREJNQ1ZtR253bkNFeC1ZdE9BbUVDcXRzamplZTNwS3pZd0phZmFlek9JdVFyQlRHVFR2WkFBYTNVSW9Hc1YxN1BIOWZVUVNYdjdaTlktMGhhVXJlei14ZmtqaUtFaGgxVDRVd1Jyc2tuSXZRMV84c2o2dDRaMmZPTi1XVGN5YUhDbjNVZjF2OFlWN2RjdmxSSlY0emU2N2pqbXRQVUdwZ2F2N3lIb0tKTE0zMmVuUjNBOU5aSTI?oc=5","date":"2026-04-08","type":"trial","source":"MSN","summary":"Ascendis Pharma A/S (ASND) reports positive week 52 data from phase 2 new InsiGHTS trial - MSN","headline":"Ascendis Pharma A/S (ASND) reports positive week 52 data from phase 2 new InsiGHTS trial","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxPemwyd1otS193NXpWSjJPMFJNcE40VVpIbDF3X041WEQ4MHVJZHp3RnJMSFNuVGI4aW9rLXo0NEw2LTgtZGNkT3F0bjd2NGRsODQ2X084NXNNYWdLVkwtZjZNX082anpLMXUxNWJqOWYxQWRmbHJSZm5fTUlXcWRMRDEtWjV4cDNkWnd5UUk0Ml9nblBwdUc0QnV4N3hobDVWNEFLWVc0dzFzM2haN1Npd1RISVFhUQ?oc=5","date":"2026-04-08","type":"pipeline","source":"Stock Titan","summary":"Ascendis Pharma (NASDAQ: ASND) to swap ADSs for ordinary shares in Nasdaq direct listing - Stock Titan","headline":"Ascendis Pharma (NASDAQ: ASND) to swap ADSs for ordinary shares in Nasdaq direct listing","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-04-08","type":"pipeline","source":"The Manila Times","summary":"Ascendis Pharma to List Ordinary Shares Directly on Nasdaq - The Manila Times","headline":"Ascendis Pharma to List Ordinary Shares Directly on Nasdaq","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxQM3ZxWFFESTBkYmc0a1h4aG9CYldSaE95Q0dhU0d4amxnN0JyamZXVEZXYnVIQjQ5MjFlQUI3SmkwX2lmRmF4eEE2Z2pfamdDT0t3MWVBYW5laUZzOVh6VTJIQjMya19ldFM1cjgzR3R1c1ktb1V1c2Z6RGNELVRGWm1Cd1JGOXNwMm5yQkY4dUlhXy1YN3RHZ2ZXVS1oQXZEME1QZFJ2Ym1LYUxvenFMNmVZUi1QZw?oc=5","date":"2026-04-08","type":"trial","source":"Stock Titan","summary":"New COACH trial Week 52 data for TransCon combo at Ascendis Pharma (ASND) - Stock Titan","headline":"New COACH trial Week 52 data for TransCon combo at Ascendis Pharma (ASND)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPZjJaRHFpTEYzVGdSZHl1VWdFXzU0SWtTWFFNd3NzSXVQQ2U4Z2FYdEd0aFNSUWlCTFl5QTRKRlJ3bm1KUU90ejVUcnd3MlFMYzVmZkVBQVMwdkVDS3RkVUVOMmJmUTZQTFRYbnZrWHBfZkZGSm9BME5BQVZWX2x1VEoxQ3Q0R05UZWowVGxFMVlUWDFBU0UycGRnQ3lLZXJoeU1wQndHYjlJZw?oc=5","date":"2026-04-08","type":"pipeline","source":"Stock Titan","summary":"Ascendis will swap every Nasdaq ADS for 1 ordinary share on April 20 - Stock Titan","headline":"Ascendis will swap every Nasdaq ADS for 1 ordinary share on April 20","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQR2ZlZnNQemVYMjFxLVRMVjJ2R0dGLXRUOUEzdGh0Z1U5b3RtSUNfajh4OGpJQlc1X2NzVTMyQXlTUlM5RmhYaTBTVWo5cjlaQXlGMzA2czdMNXZMdW1hS0sxb2RFQjR6YmJUcFR5OHYzeUt1SllyVGpEUlFucWhobXNaZDVtNnQzdEN4YWtxWV9UNkxfTkkyZVNLOG1IajJxMUc3dVBR?oc=5","date":"2026-04-07","type":"deal","source":"moomoo.com","summary":"Barclays Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $342 - moomoo.com","headline":"Barclays Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $342","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxOZnRoVk55SHdnOVdhOWo4TkNTREZPaXM3dXFJelZzLUt5Tk9pRk9UOUowQTF0TDZEcURnVkg5MUxsRWpUTnd6S0M1UlZYRlB5R3RLakttTXVkOUpzMlV6azBxQTVTRFdsdGtkQWwyRVFxWURDelZwVmFYRHJ0dmxSRmJCVzdLMGtXbThXX3dGRnNKcnFwaGh3NzhWaW1TRWR0QUl5MA?oc=5","date":"2026-04-06","type":"deal","source":"富途牛牛","summary":"Barclays Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $342 - 富途牛牛","headline":"Barclays Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $342 - 富途牛牛","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxNeTZ1VThiZUY0djk4eUFNWnI3VUN2WHdRRlBkelVFaHZ3aVFQbHFBNTFOVTJoN1p4OTFSQi1reWtXQ19hdGlQZjJBWkhTR0dScVpiMFdLLTBVOXlBZFUxclJkZ0VpUXhYVHRPQk5DRVVBNndrRThRbU12RTJISlBsc2lQelVMSFUwTnBuNVY1YTBYMTUwTjhIWmpkN3Y5UUlNRkQxZkZodnlYZVpFS25zcndXY21ZRE1HWFBCSlFOT3IwMS1SbFQzTno2VnVldklBRXNqYmIxTXFNUWE4ZEljVw?oc=5","date":"2026-04-04","type":"deal","source":"MarketBeat","summary":"Ascendis Pharma A/S (NASDAQ:ASND) Receives Consensus Recommendation of \"Moderate Buy\" from Analysts - MarketBeat","headline":"Ascendis Pharma A/S (NASDAQ:ASND) Receives Consensus Recommendation of \"Moderate Buy\" from Analysts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYkFVX3lxTE9QcFJjdmtDS1ViTlVQaDhOeDVJSGFsVV9TNTBhQnFfVUJXMDB6YUFhN1U0MVlKckF4bk1nRF9IUjJzbVBZaVpqbkdXdW9DMUs0cU1JREI0QUE5Ny1ucWljLW5B?oc=5","date":"2026-04-02","type":"pipeline","source":"Yahoo! Finance Canada","summary":"Ascendis Pharma A/S (A71.F) Stock Price, News, Quote & History - Yahoo! Finance Canada","headline":"Ascendis Pharma A/S (A71.F) Stock Price, News, Quote & History - Yahoo! Finance Canada","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxOd1RXRHAwdmstbTc2REc1LWYtWmN6VWxXSVNXOFZqS3I2Zkk5Zkh5Tk5uNHhaYmpmZFZCMXlta1B6LVp1R2tFcF9BSy1vRVdtOGRnSDlDclpITGVIOWxuNmt3cnlRbEZXa0FOeFJJZHpsTmFKX1VRd2J1X1cyT2paOFRB?oc=5","date":"2026-01-15","type":"pipeline","source":"Yahoo Finance","summary":"Ascendis Pharma A/S (ASND): A Bull Case Theory - Yahoo Finance","headline":"Ascendis Pharma A/S (ASND): A Bull Case Theory","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxNRG1Mb3kyTDc4V2VPOEw2UHVJaDdQUXNEbjRWaFVqUlVRQ2IyZjhkVjJUNDVrd1lkZ2VaUzJwN293UklkM2NoMDhCV2xMXzJKX3ByaXBlc3FjN3lwSnVyamxxWVIzWWNxcFVER0FtRFZCR3BqMmxkclBXTlMxWmZTTFhhTjJJVURJdnRlVWtkM3ZFYmdmRjNIWl9PZTFvLXpGUGhNbDJ4b0R0MFdsZnVERjRYXzNxdUx1TTJydEpJSERXbk5meVNPTm52dndTbGkzMkZmamNicHM2a0VKTmpQN1p3RUNHNWs?oc=5","date":"2026-01-05","type":"pipeline","source":"Quiver Quantitative","summary":"Ascendis Pharma A/S to Present Business Update at 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 - Quiver Quantitative","headline":"Ascendis Pharma A/S to Present Business Update at 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}